Enea TECH and Biomedical Foundation announces a ?15 million investment in Tethis S.p.A., a Milan-based company at the forefront of cancer ...

Tethis is developing innovative solutions for liquid biopsy, a non-invasive blood test that can detect traces of tumor circulating in the blood. The core of Tethis’ innovation lies in its integrated ...

Oxford University researchers have unveiled a new blood test, powered by machine learning, that shows promise in detecting ...

Guardant Health (GH) announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. “2024 was an outstanding ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. For the three-month ...

Personalized medicine is revolutionizing lung cancer treatment by tailoring approaches to genetic profiles, leading to more ...

Oxford Cancer Analytics (OXcan) has secured $11m in Series A funding for the development of its liquid biopsy blood tests for ...

New research from the University of St Andrews School of Medicine has found that biomarker testing in individuals at risk of ...

OXcan was founded in 2020 by Dr. Peter Jianrui Liu and Dr. Andreas Halner to advance early cancer detection using liquid biopsy.

Medtech Oxford Cancer Analytics (OXcan) said it has raised US$11m in Series A funding from global investors, including ...

Bone marrow biopsy is a term used to describe a surgical procedure in which a small portion of bone marrow is extracted from ...

BALTIMORE and PALO ALTO, Calif., Jan. 8, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc. , developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer ...